HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Pack Size	Availability	Price/USD	Quantity
100 μg	Inquiry	$ 243.00
1 mg	Inquiry	$ 1,632.00

Pack Size

Availability

Price/USD

Quantity

100 μg

Inquiry

$ 243.00

1 mg

Inquiry

$ 1,632.00

Description

Species	Human
Expression System	E. coli
Tag	C-His-Avi
Accession Number	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK
Synonyms	NS, KRAS, KRAS1, KRAS2, MHC, RALD, K-RAS4A, K-RAS2A, K-RAS4B, K-RAS2B, KI-RAS, RASK2, CFC2, GTPase Kras, K-Ras 2, C-K-RAS, NS3
Construction	Recombinant Biotinylated Human HLA-A11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.[Accession \|AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.